Breadcrumb

New Alliances at a Glance

Alliances At-A-Glance

To achieve our goals of bringing safe and effective medicines to patients in need, as well as achieving long-term growth, Daiichi Sankyo partners with a variety of organizations to focus on progressing promising products that complement our in-house portfolio.

Our strategy involves in-licensing new products and product candidates, acquiring companies that will drive our portfolio in key therapeutic areas, as well as partnering on specific aspects of research, development and/or commercialization.

Our decades-long history of effective collaboration exemplifies our ability to license products in and out of Daiichi Sankyo, develop and maintain valuable partnerships, and successfully complete mergers and acquisitions.

Here is a snapshot of our activity:

2017

Bristol-Myers Squibb

A research collaboration to evaluate Opdivo® (nivolumab) and DS-8201 in HER2-expressing breast and bladder cancers

2017

Max Planck Innovation GmbH and Lead Discovery Center GmbH

An agreement between Daiichi Sankyo, Max Planck Innovation and the Lead Discovery Center providing Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for the treatment of cancer to be discovered and developed at the Lead Discovery Center

2017

Heptares Therapeutics, Limited

A drug discovery and licensing agreement with Heptares Therapeutics that is focused on a single G protein-coupled receptor (GPCR) that plays a crucial role in relieving pain

2017

Kite Pharma

A strategic partnership with Kite Pharma, a subsidiary of Gilead Sciences, Inc.,  for the exclusive rights of development, manufacturing and commercialization in Japan of Kite’s cellular cancer therapy axicabtagene ciloleucel (KTE-C19)

2016

Amgen

An exclusive agreement to commercialize nine biosimilars in Japan, including several biosimilars in late stage development, including biosimilars of adalimumab, bevacizumab and trastuzumab

2016

Celixir

An agreement  with Celixir for an exclusive license in Japan to develop and market Heartcel™, an immune-modulatory progenitor (iMP) cell therapeutic agent for ischemic heart failure currently in development

2016

AgonOx, Inc.

A strategic collaboration with AgonOx, Inc. to develop an undisclosed immuno-oncology target

2016

Inspirion Delivery Sciences

A  collaboration to commercialize two abuse-deterrent opioid medications, MorphaBond™ ER and RoxyBond™, both of which feature a unique, patent-protected abuse-deterrent technology

2016

Zymeworks, Inc.

A cross-licensing and collaboration agreement to develop proprietary cancer immuno-oncology products

2015

Translational Sciences, Inc.

An exclusive licensing agreement to develop and commercialize its novel thrombus (blood clot) dissolving agent, TS23

2015

AstraZeneca

A co-commercialization agreement for Movantik®, a medication indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain

2014

Sanford-Burnham Medical Research Institute

A comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases. The collaboration is built on an open-innovation model to bridge the gap between target discovery and pre-clinical drug development.

2014

Virtici, LLC and Celdara Medical, LLC

A collaboration to jointly investigate novel therapeutic candidates and thereby further strengthen the Daiichi Sankyo developmental pipeline across multiple therapeutic areas

2014

University of California, San Francisco

A drug discovery collaboration focused on developing novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases

Note: This is not a complete list of Daiichi Sankyo alliances

PP-US-NP-0276 09/2017

Alliances At-A-Glance More Stories

Learn More

Business Development

By continuing to invest in our research and development we strive to discover and develop new therapies ...

read more ...

Alliances At A Glance Helpful Resources